Management of hereditary hypercoagulable disorders.
The clinical management of individuals with hereditary hypercoaguable disorders has evolved from initial broad recommendations of lifelong anticoagulation after first event of venous thromboembolism to a more intricate individualized risk-benefit analysis as studies have begun to delineate the complexity of interactions of acquired and hereditary factors which determine the predilection to thrombosis. The contribution of thrombophilic disorders to risk of thrombotic complications of pregnancy, organ transplantation, central venous catheter and dialysis access placement have been increasingly recognized. The risk of thrombosis must be weighed against risk of long-term anticoagulation in patients with venous thromboembolism. Thrombophilia screening in select populations may enhance outcome.
Bockenstedt
Paula L
PL
University of Michigan, 200 Barton N Drive, Ann Arbor, MI 48105, USA. pbockens@umich.edu
D000925:Anticoagulants / Q000627:therapeutic use; D025861:Blood Coagulation Disorders, Inherited / Q000150:complications / Q000188:drug therapy; D019468:Disease Management; D006801:Humans; D019851:Thrombophilia / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
D000925:Anticoagulants